Pharma/Biotech - Page 1 | TalkMarkets
All Posts > Content under Pharma/Biotech
1 to 16 of 2194 Posts
1 2 3 ... 138
Abbott (ABT) Beats Earnings And Sales In Q3, Tweaks View
Article By: Zacks Investment Research
Wednesday, October 18, 2017 10:57 AM EDT
Abbott Labs posted third quarter revenues of $6.82 billion surpassing the Zacks Consensus Estimate for revenues of $6.71 billion.
In this article: ABT
Amgen May Pull Back Before The Next Surge
Article By: Bob Lang
Wednesday, October 18, 2017 9:38 AM EDT
Will Amgen provide another ideal entry point? The chart says yes.
In this article: AMGN
Merck Upgraded To Buy From Neutral At Citi
Article By: The Fly
Wednesday, October 18, 2017 6:53 AM EDT
The analyst revised his initial PDx market estimates of $35bn to at least $50bn and increased his 2025 Keytruda forecasts from $9B to$15B.
In this article: MRK Also: LLY, RHHBY
Your Stake In The $22 Billion Dollar Cannabis Industry
Article By: Modest Money
Wednesday, October 18, 2017 4:54 AM EDT
Is now the right time to invest in the Cannabis Industry? The Cannabis Stock Index is up 26.4% month-to-date.
In this article: SMG, VRX, ABBV, INSY
You Gotta Be In It To Win It
Article By: Bespoke Investment Group
Tuesday, October 17, 2017 10:15 PM EDT
The last four months have been a very good time to be long the biotech group.
In this article: IBB
3 Market-Beating Stocks For Your 2018 Radar (With Extreme Upside Potential)
Article By: TipRanks
Monday, October 16, 2017 8:47 AM EDT
This little-known biotech stock has only received three buy ratings from top analysts in the last three months. However, these three analysts are all confident on one thing: that Gemphire has serious upside potential.
In this article: MCRB, LITE, GEMP
The Final Straw For Mallinckrodt?
Article By: Shock Exchange
Sunday, October 15, 2017 10:55 PM EDT
JAMA questioned the effectiveness of MNK's Acthar. AMA's research could be the catalyst for lawmakers to reduce Medicare/Medicaid purchases of Acthar, which is MNK's biggest seller.
In this article: MNK
Week In Review: Shanghai Pharma Bids In Cardinal China's $1.5 Billion Auction
Article By: ChinaBio® Today
Saturday, October 14, 2017 5:29 PM EDT
Shanghai Pharma (SHA: 601607) and FountainVest Partners, a China private equity fund, have submitted second-round bids for Cardinal China's (NYSE: CAH​) drug distribution operations.
In this article: CAH, CASI, CBPO, BIIB
Aurora Cannabis Inc. Vs. Aphria Inc.: Which One Is A Better Buy?
Article By: Lorimer Wilson
Saturday, October 14, 2017 2:38 PM EDT
Each company produces marijuana differently and in different parts of Canada, enabling them to better focus on gaining market share in their respective locations.
In this article: ACBFF, APHQF Also: TWMJF
How To Get Involved In The Drug Trade (It’s Not What You Think)
Article By: David Zarling
Saturday, October 14, 2017 11:58 AM EDT
Eli Lilly & Co. (LLY), one of the world’s largest drug manufacturers, has seen its stock go nowhere for 2 years. This after Lilly was up over 350% from the bottom in 2009 through September 2015. Last week, it broke out of the 2-year base.
In this article: LLY
Concern Over Valeant's Financial Controls 'Likely Just Noise,' Says Cantor
Article By: The Fly
Friday, October 13, 2017 8:17 PM EDT
Cantor Fitzgerald analyst Louise Chen says after speaking with the company, she believes the concerns are "likely just noise and cannot be strung together into an argument" that Valeant has issues with financial controls.
In this article: VRX Also: DEPO
Teva Maneuvers To Match 30% Discounts For Generic Copaxone
Article By: Shock Exchange
Friday, October 13, 2017 12:09 PM EDT
Market chatter suggests Mylan is offering 25%-30% discounts on generic Copaxone, and Teva is scrambling to match the discounts. If Teva has to lower Q4 earnings guidance investors could punish the stock.
In this article: TEVA, MYL
Allergan Says Mohawks Bought Restasis Patents With Immunity Promise
Article By: Shock Exchange
Friday, October 13, 2017 10:36 AM EDT
AGN the Mohawks brought Restasis patents with a promise of immunity. I estimate the patents are worth $14B. The patent judge want to determine if the deal was a sham.
In this article: AGN Also: MYL, TEVA
E Why Sarepta Therapeutics Inc Looks On Track For A Second DMD Approval
Article By: Samuel Rae
Wednesday, October 11, 2017 9:36 AM EDT
Here's a look at Sarepta's latest data and where it fits into the company's Duchenne muscular dystrophy (DMD) portfolio. From a trader's perspective, Sarepta looks like it could be a strong pick heading into early 2018 and beyond.
In this article: SRPT
Aurora Upsizes Financing Deal To $60 Million - Here's The Details
Article By: The Daily Marijuana Observer
Tuesday, October 10, 2017 7:00 PM EDT
Already well-capitalized, Aurora looks to accelerate its aggressive growth strategy.
In this article: ACBFF
5 Pharma & Biotech Stocks That Could Be Big Winners In Q3 Earnings
Article By: Arpita Dutt
Tuesday, October 10, 2017 4:34 PM EDT
Pharma and biotech stocks started 2017 on a strong note with this part of the market remaining in favor as the year progresses. So far this year, the Nasdaq Biotechnology Index is up 25.6%.
In this article: LLY, MRK, PFE, BIIB, VRTX Also: NVS, GILD
1 to 16 of 2194 Posts
1 2 3 ... 138